The future of myeloma therapy: moving toward safer frontline immunotherapy approaches

Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares his insights into the future of multiple myeloma treatment, highlighting the need for safer immunotherapies for frontline treatment and notes that newer therapies with lower toxicity and less frequent dosing may be key to achieving this goal. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.